MYBPC3 Antibody (H-9): sc-166403

MYBPC3 Antibody (H-9) is a mouse monoclonal IgG1 antibody that detects MYBPC3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MYBPC3, or myosin-binding protein C, cardiac, plays a crucial role in regulating cardiac muscle contraction by interacting with myosin and actin filaments within the thick filament structure of striated muscle. MYBPC3 is located in the crossbridge-bearing zone of the A bands, where MYBPC3 modulates the activity of actin-activated myosin ATPase, thereby influencing the contractile function of the heart. MYBPC3′s location in the cell is essential for effective muscle contraction and overall cardiac function. Dysregulation or mutations in MYBPC3 can lead to significant cardiac disorders, such as familial hypertrophic cardiomyopathy type 4, characterized by ventricular hypertrophy, which underscores the necessity of MYBPC3 in maintaining heart health. MYBPC3 is located on chromosome 11p11.2, and understanding MYBPC3′s function and interactions is vital for developing therapeutic strategies for heart diseases. Anti-MYBPC3 antibody (H-9) is an invaluable tool for researchers studying cardiac physiology and pathology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MYBPC3 Antibody (H-9) References:

1. Oxidative Stress in Dilated Cardiomyopathy Caused by MYBPC3 Mutation.  |  Lynch, TL., et al. 2015. Oxid Med Cell Longev. 2015: 424751. PMID: 26508994
2. MYBPC3 hypertrophic cardiomyopathy can be detected by using advanced ECG in children and young adults.  |  Fernlund, E., et al. 2016. J Electrocardiol. 49: 392-400. PMID: 27061026
3. Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPsc-Derived Cardiomyocytes.  |  Prondzynski, M., et al. 2017. Mol Ther Nucleic Acids. 7: 475-486. PMID: 28624223
4. Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity.  |  Vinodhini, MT., et al. 2018. Indian Heart J. 70: 319-322. PMID: 29716714
5. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.  |  Seeger, T., et al. 2019. Circulation. 139: 799-811. PMID: 30586709
6. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.  |  Mori, AA., et al. 2021. Forensic Sci Int Genet. 52: 102478. PMID: 33588347
7. Generation of two heterozygous MYBPC3 mutation-carrying human iPSC lines, SCVIi001-A and SCVIi002-A, for modeling hypertrophic cardiomyopathy.  |  Liu, L., et al. 2021. Stem Cell Res. 53: 102279. PMID: 33743363
8. Generation of bi-allelic MYBPC3 truncating mutant and isogenic control from an iPSC line of a patient with hypertrophic cardiomyopathy.  |  Warnecke, N., et al. 2021. Stem Cell Res. 55: 102489. PMID: 34375846
9. Identification of an elusive spliceogenic MYBPC3 variant in an otherwise genotype-negative hypertrophic cardiomyopathy pedigree.  |  Torrado, M., et al. 2022. Sci Rep. 12: 7284. PMID: 35508642
10. MicroRNA expression profiles in familial hypertrophic cardiomyopathy with myosin-binding protein C3 (MYBPC3) gene mutations.  |  Lin, LR., et al. 2022. BMC Cardiovasc Disord. 22: 278. PMID: 35717150

The preferred MYBPC3 antibody is MYBPC3 Antibody (E-7): sc-137180.